

Date: _____ Date Medication Required: _____
 Ship to: Physician Patient's Home Other

Patient Information

*Last Name:	*First Name:	Middle:	*DOB: ___/___/___	
Address:		City:	State:	Zip:
Daytime Phone:		Evening Phone:	*Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female	

Insurance Information (Attach copies of cards)

*Primary Insurance:		Secondary Insurance:		
*ID #	Group #	ID #	Group #	
City:	State:	City:	State:	

Physician Information

*Name:	*Specialty:	NPI:		
Address:		City:	State:	Zip:
*Phone #:	Secure Fax #:	Office Contact:		

Primary Diagnosis

*ICD-10 Code: _____
 Duchenne muscular dystrophy (DMD) Other: _____

Prescription Information

MEDICATION	STRENGTH	*DIRECTIONS	QUANTITY	REFILLS
Vyondys 53 (golodirsen)				

Clinical Information ***** Please submit supporting clinical documentation *****

* THERAPY TYPE (choose one): INITIAL THERAPY CONTINUATION OF THERAPY - Therapy start date: _____

- Has patient had a positive response to the prescribed therapy within the last 6 months?
 Yes ****Mark all that apply**** No Not applicable
 Ambulatory function with a 6 minute walk test distance (6MWT) ≥ 250 m: _____ m Date: _____
 Stable cardiac function with left ventricular ejection fraction (LVEF) > 50%: _____ % Date: _____
 Stable pulmonary function with predicted forced vital capacity (FVC) ≥ 50%: _____ % Date: _____
 Patient has received medication via healthcare insurer and medical record shows improved, or stable, LVEF and FVC assessed within the last 6 months:
 Baseline LVEF: _____ %, Date: _____ Current LVEF: _____ % Date: _____
 Baseline FVC: _____ % Date: _____ Current FVC: _____ % Date: _____
 Other: _____
- Has patient been assessed by a neurologist within the last 6 months? Yes No
- Is Vyondys 53 prescribed concurrently with an oral corticosteroid?
 Yes: _____ No No, contraindicated/intolerant
- Is Vyondys 53 prescribed concurrently with other exon-skipping therapies (e.g. Amondys 45, Exondys 51, Viltepso)? Yes No
- Is mutation amenable to exon 53 skipping confirmed with genetic testing? Yes, mutation: _____ - _____ No
- Please document patient's weight: _____ kg

Complete this section ONLY if the patient is initiating therapy OR if the patient is new to this health plan:

- Is therapy prescribed by or in consultation with a neurologist? Yes No
- Has the patient had an inadequate response (evidence by significant decline in 6MWT, LVEF, or FVC) despite adherent use of an oral corticosteroid (e.g., prednisone, Emflaza™) for ≥ 6 months? Yes No No, contraindicated/intolerant

Please continue to page 2



Telephone: (800) 514-0083 option 2
Fax: (866) 374-1579

Golodirsen (Vyondys 53)
Prior Authorization Form/Prescription

Date: Date Medication Required:
Ship to: Physician Patient's Home Other

Patient Name: DOB:

9. Has patient had an assessment of all of the following within the last 30 days?

- Yes No
Ambulatory function with a 6 minute walk test distance (6MWT) >= 250 m
Stable cardiac function with left ventricular ejection fraction (LVEF) > 50%
Stable pulmonary function with predicted forced vital capacity (FVC) >= 50%

Complete this section ONLY for indications other than DMD:

10. Has patient tried and failed, or is contraindicated to, accepted standards of care? Yes No

If yes, submit documentation and answer the following:

- Please list all previous therapies:
Was patient adherent to previously tried therapies? Yes No No, patient intolerant to drug

Physician's Signature: Date: DAW

INFORMATION BELOW IS TO BE COMPLETE BY THE HEALTH PLAN/EPS PA STAFF

Authorization Information

Table with 2 columns: Authorization number, Decision Due Date, J-Code, Coverage, Line of Business, Benefit. Includes checkboxes for Commercial, Medicaid, Health Insurance Marketplace, Medicare, State excludes, COB, Medical, Pharmacy.

*Criteria:
Centene Policy
Date Policy last reviewed/approved by plan (we want to be sure we are using the version approved by your plan):
State Specific (please include policy)